Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Breast biopsy & localization · New York | Breast biopsy & localization · Pennsylvania | |
|---|---|---|
| Surgeons, 2024 | 288 | 180 |
| Medicare fee-for-service cases | 16,847 | 9,684 |
| Growth since 2019 (Medicare FFS) | +0.4%/yr | −1.2%/yr |
| Forecast cases (Medicare FFS) | 18,000 in 2030 | 10,100 in 2030 |
| Forecast growth | +1.1%/yr to 2030 | +0.8%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 9.9 | 7.6 |
| Medicare Advantage share | 57% | 58% |
| Out of hospital | 43% (+2 pts since 2019) | 8% (+1 pts since 2019) |
| Cases per surgeon | 58 | 54 |
| Top 10 surgeons' share | 13% | 17% |
| Surgeons growing | 59 | 28 |
| New since the base year | 54 | 27 |
| Likely to stop billing it | 29 by 2026 | 36 by 2026 |
| Forecast miss, 1 year (procedure) | 3% | 3% |
| Company payments per surgeon | $2,341 | $1,732 |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.